Akt promotes irradiation-induced regulatory T-cell survival in hepatocellular carcinoma

American Journal of the Medical Sciences

Volumn 346, Issue 2, 2013, Pages 123-127

  Li, Chuan Gang ^a   He, Mei Rong ^a   Wu, Feng Lin ^a   Li, Ying Jia ^a   Sun, Ai Min ^b  

^a Department of Ultrasound Diagnosis ^*  (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Hepatocellular carcinoma; Liver; Radiotherapy; Regulatory T cell

Indexed keywords

PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IRRADIATION; LIVER CELL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; WESTERN BLOTTING;

EID: 84880780390     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31826ceed0     Document Type: Article

References (15)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
2. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 2011;11:119-30.
3. Long SA, Buckner JH. CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. J Immunol 2011;187:2061-6.
4. Buckner JH. Mechanisms of impaired regulation by CD4+CD25 +FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010;10:849-59.
5. Ethan M. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity 2009;30:636-45.
6. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
7. Watanabe M, Oda J, Amarante M. Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev 2010;29:569-79.
8. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009;1174: 99-106.
9. Martelli AM, Evangelisti C, Chappell W, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011;25:1064-79.
10. Freudlsperger C, Burnett JR, Friedman JA, et al. EGFR-PI3KAKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 2010;15:63-74.
11. Gills J, Dennis P. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009;11:102-10.
12. Liu T, Song CH, Liu AM, et al. Forkhead box P3+ T cells express interleukin-17 in nasal mucosa of patients with both allergic rhinitis and polyposis. Clin Exp Immunol 2011;163:59-64.
13. Chen YL, Law PY, Loh HH. Inhibition of Akt/protein kinase B signaling by naltrindole in small cell lung cancer cells. Cancer Res 2004; 64:8723-30.
14. Brognard J, Clark AS, Ni Y, et al Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-97.
15. Wang M, Gou X, Wang L. Protein kinase B promotes radiationinduced regulatory T cell survival in bladder carcinoma. Scand J Immunol 2012;76:70-4.